MRK Merck & Co

For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of its mission to save and improve lives. It demonstrates its commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals - including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases - as we aspire to be the premier research-intensive biopharmaceutical company in the world.

Company profile

Kenneth Frazier
Fiscal year end
Former names
IRS number

MRK stock data



5 May 21
4 Aug 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Merck & Co earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 7.02B 7.02B 7.02B 7.02B 7.02B 7.02B
Cash burn (monthly) 380.67M 36.42M (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn)
Cash used (since last report) 1.57B 150.67M n/a n/a n/a n/a
Cash remaining 5.45B 6.87B n/a n/a n/a n/a
Runway (months of cash) 14.3 188.7 n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
30 Jun 21 Coe Mary Ellen Phantom Stock Common Stock Grant Aquire A No No 77.77 417.899 32.5K 11,796.751
30 Jun 21 Christine E Seidman Phantom Stock Common Stock Grant Aquire A No No 77.77 208.95 16.25K 6,571.432
30 Jun 21 Glocer Thomas H Phantom Stock Common Stock Grant Aquire A No No 77.77 112.511 8.75K 78,357.795
30 Jun 21 Wendell Peter C Phantom Stock Common Stock Grant Aquire A No No 77.77 385.753 30K 107,613.174

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

71.1% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 2499 2538 -1.5%
Opened positions 135 296 -54.4%
Closed positions 174 161 +8.1%
Increased positions 1167 1136 +2.7%
Reduced positions 950 831 +14.3%
13F shares
Current Prev Q Change
Total value 138.78B 151.37B -8.3%
Total shares 1.8B 1.85B -2.7%
Total puts 14.51M 13.88M +4.5%
Total calls 16.53M 18.03M -8.3%
Total put/call ratio 0.9 0.8 +14.0%
Largest owners
Shares Value Change
Vanguard 225.21M $17.36B +8.1%
BLK Blackrock 193.93M $14.95B -0.6%
STT State Street 112.69M $8.76B -1.3%
Geode Capital Management 42.77M $3.29B +1.6%
Wellington Management 39.6M $3.05B -2.6%
BAC Bank Of America 36.61M $2.82B -8.8%
BEN Franklin Resources 35.46M $2.73B +20.6%
Capital International Investors 33.18M $2.56B -4.2%
NTRS Northern Trust 32.09M $2.47B -2.4%
BK Bank Of New York Mellon 30.57M $2.36B -3.9%
Largest transactions
Shares Bought/sold Change
Norges Bank 0 -27.52M EXIT
Vanguard 225.21M +16.8M +8.1%
Charles Schwab Investment Management 22.7M +11.1M +95.6%
BRK.A Berkshire Hathaway 17.88M -10.82M -37.7%
Capital World Investors 12.63M -7.8M -38.2%
BEN Franklin Resources 35.46M +6.06M +20.6%
RY Royal Bank Of Canada 15.36M -6.02M -28.2%
Swedbank 0 -4.39M EXIT
Nuveen Asset Management 19.78M -4.31M -17.9%
IVZ Invesco 11.22M -4.04M -26.5%
Content analysis
H.S. sophomore Bad
New words: abnormal, adapt, adapted, Alydia, amenable, antibacterial, anticancer, anticompetitive, antifungal, Apotex, appointed, argument, Artiva, ASCT, autoimmune, belzutifan, bleeding, Boston, bound, capsid, carbapenem, Caroline, Centene, CFO, Clyburn, comparison, conform, consultation, curative, delivery, device, DFS, diagnosed, differentiate, dMMR, durability, Dutch, EFS, entitled, entry, escrow, estrogen, expert, explore, failed, feedback, fill, fluoropyrimidine, Francisco, Frank, Gilead, hemorrhage, Humana, inactivated, inclusive, India, Indian, intelligence, Janssen, Johnson, joined, kidney, left, lenacapavir, Litchfield, mandate, maternal, meaningfully, Michael, Microspherix, Minnesota, monohydrate, morbidity, mutually, Nally, negligible, nephrectomy, Nexplanon, notably, ODAC, OncoImmune, outpatient, Pandion, passing, pCR, Pentavalent, persist, Pool, postpartum, precedent, precision, preclude, premium, Preventice, proceed, proprietary, recall, recast, Reciprocally, referenced, release, relebactum, resection, revert, revolving, Robert, RotaTeq, San, satisfaction, shareable, sorafenib, span, split, sterility, substance, successfully, sued, surgical, technical, threshold, timeline, UHC, unrelated, unsubordinated, uterine, Vaqta, Verquvo, viable, violated, voluntarily, voluntary, voted, wholly, withdrawal, withdrawing
Removed: aaa, ability, abiraterone, advance, amendment, America, American, Antelliq, arrangement, ASC, atherosclerotic, Attorney, auto, bacteremia, baseline, bench, Branch, brentuximab, Canada, card, Cardiology, cediranib, Center, certify, College, complicated, composite, confident, contemporary, coordinate, cotransporter, creatinine, Cubicin, CV, daptomycin, Daubert, debilitating, declining, decrease, demonstrating, diversity, divesting, DMC, dosage, doubling, effort, elbasvir, Emend, England, enrolled, ensure, entirety, enzalutamide, ertugliflozin, estimating, examined, False, finalization, formally, fundamental, gene, genetic, genotype, germline, grazoprevir, GT, Hong, hormonal, HRR, infarction, inventory, Journal, Kong, Latin, led, litigate, MACE, mCRPC, meaningful, misrepresented, modified, Moody, moved, muscle, myocardial, NaN, nasopharyngeal, nausea, NCI, NMIBC, noncontrolling, nonfatal, NRG, observed, patient, PMBCL, PN, POLO, Poor, population, positively, PROfound, prospectively, published, rapid, rare, recombination, reduction, renewing, replacing, rescheduled, reserved, retained, retrospective, reversed, rule, schedule, SCLC, serum, Session, showed, skin, somatic, sponsored, Steglatro, stipulated, stroke, student, susceptible, suspected, test, tested, Teva, travel, USA, Utah, vedotin, Vioxx, vomiting, Zepatier


Formulation for parenteral administration
3 Aug 21
The instant invention provides pharmaceutical formulations for a long acting injectable drug product comprising a suspension of doravirine for parenteral administration via intramuscular or subcutaneous routes.
Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor
3 Aug 21
Use of a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor for the treatment of diabetes and related conditions is disclosed.
Vaccine comprising a PCV2 ORF2 protein of genotype 2b
3 Aug 21
The present invention pertains to a vaccine comprising an ORF2 encoded protein of porcine circo virus 2 (PCV2) and a pharmaceutically acceptable carrier, for use in a method to protect a pig against an infection with porcine circo virus type 2 by administering the vaccine to the pig, wherein the vaccine comprises less than 20 μg per dose of the ORF2 encoded protein, the protein being of a porcine circo virus of genotype 2b.
29 Jul 21
Inventors: Tjeerd A. Barf, Christiaan Gerardus Johannes Maria Jans, Adrianus Petrus Antonius de Man, Arthur A. Oubrie, Hans C.A. Raaijmakers, Johannes Bernardus Maria Rewinkel, Jan Gerard Sterrenburg, Jacobus C.H.M. Wijkmans
Method and system for tracking health in animal populations
27 Jul 21
An animal health monitoring system includes a plurality of animal tag assemblies configured for being disposed on members of an animal population, each of the animal tag assemblies including one or more sensors configured to measure one or more animal characteristics of a member of the animal population.